CNBX · CNBX Pharmaceuticals Inc. · Executive Compensation
$0.00
+0.00 (+0.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 24, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Jun 24, 2026
Market Cap
$160,576
Shares
1.61B
Volume · Oct 2
500K
Avg daily vol (3M)
8.24M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Sanja Goldberg | Chief Technology Officer | Appointed | 2022-07-25 |
| Eyal Ballan | Chief Technology Officer | Resigned | 2022-07-25 |